- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05354050
Pharmacokinetic Study of DARE-BV1
April 28, 2022 updated by: Daré Bioscience, Inc.
A Phase 1 Single-center Pharmacokinetic Study of DARE-BV1 in Healthy Female Subjects
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
Study Overview
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Phase Services, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subjects must be females >= 18 years of age with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
- Subjects may engage in heterosexual intercourse between Screening and Day-1, but must agree to abstain from sexual intercourse and/or sexual activity throughout the 7 days following treatment.
- Subjects of childbearing potential should use adequate birth control between Screening and Day 1 if engaging in heterosexual intercourse, and should not plan on becoming pregnant for the duration of the study. Acceptable forms of birth control include oral contraceptives ("the pill"), intrauterine devices (IUDs), contraceptive implants under the skin, patches or injections, and non-polyurethane condoms (e.g., latex, polyisoprene) without spermicide. Subjects in same sex relationships, or monogamous relationships with vasectomized males, may also participate. Abstinence may also be acceptable, per the Investigator's judgment. Oral or transdermal hormonal contraceptives must be in use for 1 full cycle (e.g., 4 to 8 weeks) prior to study drug application. Injectable or implanted contraceptives (e.g., Depo-Provera, Nexplanon, or hormonal IUD) must have been injected/inserted at least 7 days prior to study drug application.
Subjects who are not of childbearing potential will not need a urine pregnancy test prior to dosing or at subsequent visits. Subjects are considered to be of non-child bearing potential if one of the following is satisfied:
- Postmenopausal for at least 1 year prior to the Screening Visit (Visit 1) (defined as amenorrheic for more than 1 continuous year), or
- Surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) at least 6 months before first dose, or
- Non-surgical permanent sterilization procedure performed at least 3 months prior to study drug application.
- Subjects must be willing to refrain from the use of all intra-vaginal products (e.g., douches, feminine deodorant sprays, female condoms, spermicides, vaginal moisturizers or lubricants, tampons, vaginal birth control rings [e.g., NuvaRing®], and diaphragms) through the study or Study Exit/Early Discontinuation.
Exclusion Criteria:
- Subjects with active BV, vulvovaginitis, or other active infectious causes of cervicitis, vaginitis, or vulvitis, based on the results of the thorough clinical assessments and testing as described above or genital lesions or ulcers consistent with HPV, Herpes simplex, syphilis, chancroid, etc.). Subjects with a history of genital herpes or condylomata who have been asymptomatic for at least 6 months may be considered for eligibility.
- Potential subjects who are pregnant or are breastfeeding or, if of child-bearing potential, unwilling to practice acceptable means of birth control or abstinence during the study as described above.
- Subjects with a vaginal, vulvar, or genitourinary condition that, according to the Investigator's judgment, may confound the interpretation of clinical assessments. This includes urinary tract infections requiring antibiotics.
- Subjects with a history of regional enteritis, ulcerative colitis, or a history of Clostridium difficile-associated diarrhea.
- Subjects with known current drug or alcohol abuse that could impact study compliance.
- Subjects currently receiving or who have received antifungal or antibacterial therapy (systemic or intravaginal) within 14 days of the Screening Visit (Visit 1).
- Subjects who have used any other investigational product within 30 days of the Screening Visit (Visit 1).
- Subjects with HPV 16 or 18 at screening (performed on subjects >25 years old).
- Subjects with known sensitivity to clindamycin phosphate or other lincosamides or any of the inactive ingredients in the study drug.
- Subjects with a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with study participation or study treatment administration or could interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DARE-BV1
|
2% Clindamycin 100 MG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the Pharmacokinetics (PK)
Time Frame: 7 days
|
Evaluate the PK of a single dose of DARE-BV1 in healthy female subjects by assessment of plasma and vaginal clindamycin concentrations
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability by evaluation of Treatment Emergent Adverse Events
Time Frame: 21 days
|
Assess the safety and tolerability of DARE-BV1 by looking at TEAEs & local site reactions
|
21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Christine Mauck, MD, Daré Bioscience, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 2020
Primary Completion (Actual)
November 18, 2020
Study Completion (Actual)
December 2, 2020
Study Registration Dates
First Submitted
April 25, 2022
First Submitted That Met QC Criteria
April 28, 2022
First Posted (Actual)
April 29, 2022
Study Record Updates
Last Update Posted (Actual)
April 29, 2022
Last Update Submitted That Met QC Criteria
April 28, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DARE-BV1-PK1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Vaginosis
-
Alfasigma S.p.A.ParexelTerminatedBACTERIAL VAGINOSISUnited States
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Unity Health TorontoCompleted
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingBacterial Vaginoses
Clinical Trials on DARE-BV1
-
XtremeVRI AGAristotle University Of Thessaloniki; Klinik Hirslanden, Zurich; Greek Alzheimer...CompletedHealthy | Mild Cognitive Impairment, So Stated | Mild Dementia
-
Daré Bioscience, Inc.Completed